Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN D UPDEGROVE

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1518933308
CMS profile
205052
Location
CORSICANA, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$23.03

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $23.03 1

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Boston Scientific Corporation $23.03 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN D UPDEGROVE

NPI 1518933308 · CMS profile ID 205052

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

CORSICANA, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1518933308?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN D UPDEGROVE, NPI 1518933308, CMS profile ID 205052. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1518933308?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). JOHN D UPDEGROVE, NPI 1518933308, CMS profile ID 205052. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1518933308?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
JOHN D UPDEGROVE, NPI 1518933308, CMS profile ID 205052, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1518933308?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $23.03 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boston Scientific Corporation $23.0301/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1092602284 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2022 $27.77 1
PY2023 $65.25 1
PY2024 $23.03 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2022, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $314,315.48 99
PY2024 Principal investigator $273,588.23 61
PY2023 Principal investigator $155,995.83 32
PY2022 Principal investigator $47,617.22 8
PY2021 Principal investigator $19,079.96 12
PY2020 Principal investigator $37,064.71 15
PY2019 Principal investigator $38,041.05 14

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

61 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca UK Limited $358.84 12/31/2024 Non-covered Recipient Entity
MEDICAL AND SURGICAL ASSOCIATES OF CORSICANA
a randomized,double blind,multicenter,parallel group,phase IIIb 52 week study evaluating the efficacy and safety of PT027 compared with PT007 administered as needed in participants 12 to under 18 years of age with asthma ACADIA No dispute reported 06/30/2026 1155803522
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $9,363.90 12/26/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144237330
Principal investigator 1 Genentech, Inc. $5,680.00 12/13/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1133389636
Principal investigator 1 Genentech, Inc. $500.00 12/13/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1133389640
Principal investigator 1 Genentech, Inc. $5,210.00 12/11/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1133389638
Principal investigator 1 Genentech, Inc. $8,303.00 12/10/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1133389632
Principal investigator 1 Genentech, Inc. $350.00 12/10/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1133389642
Principal investigator 1 SANOFI US SERVICES INC. $3,715.46 12/09/2024 Non-covered Recipient Entity
Corsicana Medical Research, Llc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128725238
Principal investigator 1 Genentech, Inc. $750.00 12/05/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1133389630
Principal investigator 1 Genentech, Inc. $300.00 12/05/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1133389634
Principal investigator 1 Genentech, Inc. $750.00 12/02/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1133389628
Principal investigator 1 Genentech, Inc. $350.00 11/21/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1133389626
Principal investigator 1 SANOFI US SERVICES INC. $5,918.22 11/12/2024 Non-covered Recipient Entity
Corsicana Medical Research, Llc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128725214
Principal investigator 1 Genentech, Inc. $11,822.00 10/25/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1133389624
Principal investigator 1 Genentech, Inc. $9,781.00 10/24/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1133389614
Principal investigator 1 Genentech, Inc. $172.00 10/24/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1133389620
Principal investigator 1 Genentech, Inc. $450.00 10/22/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1133389608
Principal investigator 1 Genentech, Inc. $300.00 10/22/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1133389610
Principal investigator 1 Genentech, Inc. $450.00 10/22/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1133389622
Principal investigator 1 Genentech, Inc. $149.80 10/11/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1133389616
Principal investigator 1 SANOFI US SERVICES INC. $1,750.00 10/07/2024 Non-covered Recipient Entity
Corsicana Medical Research, Llc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128725160
Principal investigator 1 Genentech, Inc. $815.00 10/02/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1133389606
Principal investigator 1 Genentech, Inc. $887.60 10/02/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1133389612
Principal investigator 1 Genentech, Inc. $5,210.00 10/02/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1133389618
Principal investigator 1 Genentech, Inc. $250.00 09/12/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1133389600
Principal investigator 1 Genentech, Inc. $350.00 09/12/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1133389602
Principal investigator 1 Genentech, Inc. $350.00 09/12/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1133389604
Principal investigator 1 SANOFI US SERVICES INC. $2,415.14 09/09/2024 Non-covered Recipient Entity
Corsicana Medical Research, Llc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128725150
Principal investigator 1 Genentech, Inc. $8,904.00 09/05/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1133389582
Principal investigator 1 Genentech, Inc. $11,440.00 08/23/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1133389584
Principal investigator 1 Genentech, Inc. $172.00 08/23/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1133389592
Principal investigator 1 Genentech, Inc. $473.00 08/23/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1133389596
Principal investigator 1 SANOFI US SERVICES INC. $5,600.00 08/12/2024 Non-covered Recipient Entity
Corsicana Medical Research, Llc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128725120
Principal investigator 1 Genentech, Inc. $6,624.00 08/06/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1133389586
Principal investigator 1 Genentech, Inc. $600.00 08/02/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1133389588
Principal investigator 1 Genentech, Inc. $2,793.00 08/02/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1133389590
Principal investigator 1 SANOFI US SERVICES INC. $3,775.00 07/29/2024 Non-covered Recipient Entity
Corsicana Medical Research, Llc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128725138
Principal investigator 1 AstraZeneca UK Limited $9,500.00 07/19/2024 Non-covered Recipient Entity
MEDICAL AND SURGICAL ASSOCIATES OF CORSICANA
a randomized,double blind,multicenter,parallel group,phase IIIb 52 week study evaluating the efficacy and safety of PT027 compared with PT007 administered as needed in participants 12 to under 18 years of age with asthma ACADIA No dispute reported 06/30/2026 1110848055
Principal investigator 1 Genentech, Inc. $10,278.00 07/19/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1133389594
Principal investigator 1 SANOFI US SERVICES INC. $5,968.18 07/08/2024 Non-covered Recipient Entity
Corsicana Medical Research, Llc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128725110
Principal investigator 1 Genentech, Inc. $10,640.00 07/03/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1133389598
Principal investigator 1 Genentech, Inc. $1,500.00 06/07/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1133389578
Principal investigator 1 SANOFI US SERVICES INC. $6,170.00 06/04/2024 Non-covered Recipient Entity
Corsicana Medical Research, Llc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128725112
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,500.00 05/30/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144237246
Principal investigator 1 Genentech, Inc. $8,500.00 05/28/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1133389574
Principal investigator 1 Genentech, Inc. $1,800.00 05/28/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1133389580
Principal investigator 1 Genentech, Inc. $43,452.00 05/24/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1133389572
Principal investigator 1 Genentech, Inc. $238.21 05/24/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1133389576
Principal investigator 1 SANOFI US SERVICES INC. $15,765.84 04/29/2024 Non-covered Recipient Entity
Corsicana Medical Research, Llc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128725100
Principal investigator 1 GlaxoSmithKline, LLC. $1,680.84 04/12/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT No dispute reported 06/30/2026 1127535576
Principal investigator 1 Genentech, Inc. $14,292.00 04/01/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1133389570
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $409.20 03/25/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1144237400
Principal investigator 1 SANOFI US SERVICES INC. $500.00 03/04/2024 Non-covered Recipient Entity
Corsicana Medical Research, Llc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128725086
Principal investigator 1 Genentech, Inc. $900.00 02/23/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1133389560
Principal investigator 1 Genentech, Inc. $300.00 02/23/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1133389562
Principal investigator 1 Genentech, Inc. $383.00 02/23/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1133389568
Principal investigator 1 SANOFI US SERVICES INC. $2,600.00 01/29/2024 Non-covered Recipient Entity
Corsicana Medical Research, Llc
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1128725072
Principal investigator 1 Genentech, Inc. $400.00 01/24/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1133389556
Principal investigator 1 Genentech, Inc. $12,368.00 01/24/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1133389564
Principal investigator 1 Genentech, Inc. $960.00 01/24/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1133389566
Principal investigator 1 Genentech, Inc. $400.00 01/03/2024 Non-covered Recipient Entity
CORSICANA MEDICAL RESEARCH
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1133389558